Markets

CytoDyn: DSMC Recommends To Continue Leronlimab COVID-19 Registrational Trial

(RTTNews) - CytoDyn Inc. announced recommendations from the Data Safety Monitoring Committee following its review of the interim analysis of the company's Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19. The Committee recommended the trial continue without modification to achieve the primary endpoint and requested another interim analysis when enrollment reaches 75% level (or 293 patients) to review patient mortality and other clinical outcome data between leronlimab and placebo.

The company's phase 2b/3 trial to evaluate the efficacy and safety of leronlimab for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study.

CytoDyn's CEO, Nader Pourhassan, said: "We are seeking ongoing guidance from the U.S. Food and Drug Administration and regulatory agencies in other countries for a swift regulatory approval pathway for leronlimab to treat COVID-19."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More